Management of Methotrexate-Induced Leucopenia

Prevention and Treatment

The American Academy of Dermatology recommends daily folic acid supplementation (1 mg/day for 6 days/week) to all patients on methotrexate to prevent leucopenia 1
Regular monitoring of complete blood count is essential for early detection of leucopenia, as recommended by the British Journal of Dermatology 2
Folic acid supplementation (1-5 mg/day) during recovery phase is recommended, as suggested by the Journal of the American Academy of Dermatology 1
Subcutaneous administration of methotrexate may improve bioavailability and reduce side effects, as reported by the Journal of the American Academy of Dermatology 3, 4
The risk of methotrexate-induced leucopenia can be reduced by adjusting methotrexate dosing based on renal function, and avoiding drug interactions that may increase methotrexate toxicity, as recommended by the Journal of the American Academy of Dermatology 1, 3
Monitoring for other potential methotrexate toxicities, including hepatotoxicity and pneumonitis, is crucial, as reported by Gut 5
The risk of leucopenia can develop suddenly and unpredictably even after years of therapy, and therefore, long-term monitoring is necessary, as reported by Gut 6

Higher doses of folic acid and leucovorin may be used as rescue therapy for significant methotrexate toxicities, as recommended by the Mayo Clinic Proceedings 7, 8

Patients with renal insufficiency are at higher risk for methotrexate toxicity and require dose adjustments, with the British Journal of Dermatology recommending to avoid methotrexate in patients with creatinine clearance <20 mL/min and reduce dose by 50% for those with clearance between 20-50 mL/min 9
Preventive folic acid supplementation (1 mg/day) is recommended for patients on regular methotrexate therapy to reduce adverse effects, according to the Mayo Clinic Proceedings 7, 8
For patients receiving intrathecal methotrexate, oral leucovorin (10 mg) may be administered twice daily beginning on the day of treatment and continuing for 3 days to mitigate systemic toxicity, as suggested by the Journal of the National Comprehensive Cancer Network 10, 11

Monitor complete blood count, liver function tests, and renal function tests regularly during methotrexate therapy to detect early signs of toxicity, as recommended by Praxis Medical Insights 12